N4 PHARMA PLC — Share Issue/Capital Change 2017

May 3, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0879E

Verona Pharma PLC

03 May 2017

Verona Pharma plc

("Verona Pharma" or the "Company")

Block Listing Application and Review

3 May 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, today announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 2,183,491 ordinary shares of £0.05 each to be admitted to trading on AIM as an extension of the block listing issued in respect of ordinary shares of £0.05 each (the "Ordinary Shares") which may arise pursuant to the exercise of warrants issued in connection with the placing completed in July 2016 (the "2016 Warrant Shares") as announced on 29 July 2016.

The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its block listing facility (all figures relate to Ordinary Shares in the table below):

Name of company:		Verona Pharma plc
Name of scheme:		2016 Warrant Shares
Period of return:	From:	29/07/2016	To:	03/05/2017
Number and class of securities not issued/allotted under scheme(s) from previous return (following 50/1 share consolidation announced on 08/02/2017):		10,262,879
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		2,183,491
Less:  Number of securities issued/allotted under scheme(s) during period:		0
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		12,446,370
Number and class of share(s) (amount of stock/debit securities) originally admitted and the Date of Admission:		10,262,879 on 29/07/2016
Total number of shares in issue at the end of the period:		99,014,164

Name of contact:	Claire Poll
Telephone number of contact:	+44 (0)20 3283 4200
Date:	03/05/2017

-Ends-

For further information please contact:

Verona Pharma plc	Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
N+1 Singer	Tel: +44 (0)20 7496 3000
Aubrey Powell / James White/ Alex Laughton-Scott
FTI Consulting	Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins

Notes to Editors

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRSSMFDDFWSELI